MedTrace Logo

A Trial of TTA-121 on Autism Spectrum Disorder

NCT03466671 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2019-12-20

No results posted yet for this study

Summary

To test efficacy and safety of a novel nasal spray of oxytocin on social deifies in autism spectrum disorder, and To compare effect sizes of different doses

Conditions

Interventions

DRUG

TTA-121

A nove intranasal spray of oxytocin and placebo

Sponsors & Collaborators

  • Japan Agency for Medical Research and Development

    collaborator OTHER_GOV

  • Hamamatsu University

    lead OTHER

Principal Investigators

  • Hidenori Yamasue, MD, PhD · Department of Psychiatry, Hamamatsu University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
54 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2020-03-16
Completion
2020-03-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03466671 on ClinicalTrials.gov